Klf1, suggesting a model of cooperative inhibition by epigenetic modifiers. These data demonstrate a dual role for TET2 in promoting and inhibiting HSC differentiation, the loss of which, along with DNMT3A, obstructs differentiation, leading to transformation.
DNA methylation at CpG dinucleotides has a critical role in regulating gene expression in higher organisms. DNA methylation (5mC) is introduced at cytosines by DNA methyltransferases 3A and 3B (DNMT3A and DNMT3B) and is maintained by DNMT1. The ten-eleven translocation (TET) family of proteins (TET1, TET2 and TET3) can oxidize methylated cytosine to 5-hydroxymethylcytosine (5hmC) 1 , a mark not effectively maintained by DNMT1, leading to loss of DNA methylation as cells divide 2 . Thus, action of these two protein families can lead to opposite results: addition or removal of methylation. Notably, they are also epistatic, as hydroxymethylation depends on the presence of 5mC marks introduced by DNMTs.
Mutations in DNMT3A and TET2 are frequent in hematological malignancies, occurring in a comparable range of lymphoid and myeloid disorders [3] [4] [5] [6] [7] [8] [9] [10] . Furthermore, mutations in both are common in individuals with clonal hematopoiesis associated with aging [11] [12] [13] , likely owing to selective expansion of variant HSCs. DNMT3A and TET2 mutations likely arise in HSCs, conferring a competitive advantage 14 , as mutations can be found in HSCs as well as the malignant clone in patients 15, 16 .
Loss of TET2 or DNMT3A also affects HSCs in mice. Conditional ablation of Dnmt3a resulted in accumulation of HSCs, hampered differentiation and resulted in multiple malignancies [17] [18] [19] . Similarly, Tet2 −/− progenitors outcompete their normal counterparts and engender myeloid expansion reminiscent of chronic myelomonocytic leukemia (CMML) [20] [21] [22] [23] . Yet, how loss of function of these epigenetic regulators leads to aberrant HSC function and malignancy is still poorly understood.
In some studies, TET2 mutations correlated with decreased global 5hmC and increased 5mC levels in patients with acute myeloid leukemia (AML) [24] [25] [26] . In contrast, DNMT3A mutations lead to global hypomethylation with localized hypermethylation 27 . Although these contrasting methylation changes are broadly consistent with the current view of the biochemical actions of these regulators on DNA (writing versus erasing 5mC), the resulting clinical outcomes are paradoxically similar, suggesting that these proteins also work in parallel to generate a similar cellular end result. Reinforcing this view is the observation that, in addition to being mutated independently, DNMT3A and TET2 are found to be co-mutated in some malignancies. In The Cancer Genome Atlas (TCGA) AML cohort, 6 of 17 patients with TET2 mutations also have mutations in DNMT3A (χ 2 test P value = 0.0357). Likewise, in some T cell lymphoma subtypes, over 80% of patients with DNMT3A mutations also carry TET2 mutations [28] [29] [30] . Together, these findings suggest cooperation between these DNA-modifying enzymes. To explore these simultaneously parallel and antagonistic roles, we examined the roles of TET2 and DNMT3A using single-and double-knockout mice, focusing on HSCs as the target of initial changes that set the stage for the development of malignancy.
RESULTS

Tet2 and Dnmt3a loss induces myeloid and lymphoid disease
We crossed Dnmt3a conditional knockout mice (Dnmt3a fl/fl ; Mx1cre) 17 with Tet2 −/− mice 20 to create Dnmt3a-Tet2 double-knockout DNMT3A and TET2 compete and cooperate to repress lineage-specific transcription factors in hematopoietic stem cells mice and controls (Supplementary Fig. 1a ). Control mice included wild-type, Dnmt3a −/− (as referred to after induced ablation of Dnmt3a) and Tet2 −/− mice. Tet2 ablation induces expansion of mutant hematopoietic stem and progenitors cells (HSPCs) in comparison to wild-type counterparts [20] [21] [22] [23] and increases serial replating capacity. We compared serial replating capacity in methylcellulose for all four genotypes, finding that double-knockout cells exhibited the highest activity (Supplementary Fig. 1b ) and appeared least differentiated (Supplementary Fig. 1c ). To examine HSPC competitiveness in vivo, we performed whole bone marrow transplantation (BMT) with cells of each genotype in competition with wild-type cells. The order of genotypes by engraftment activity from greatest to least was double knockout > Tet2 −/− > Dnmt3a −/− ~wild type in total nucleated peripheral blood. In the myeloid compartment, both double-knockout and Tet2 −/− HSPCs showed higher rates of engraftment than Dnmt3a −/− counterparts (Fig. 1a) . These results indicate that Dnmt3a loss augments the competitive advantage of Tet2 −/− cells.
Mice transplanted with double-knockout bone marrow developed hematological disease earliest ( Fig. 1b) , showing anemia and monocytosis as early as 4 months after transplantation ( Fig. 1c) . Peripheral blood from moribund mice showed a marked myeloid bias in mice transplanted with Tet2 −/− and double-knockout cells ( Fig. 1d,e ) and an erythropoiesis deficiency in double-knockout recipients ( Fig. 1f,g) . Histology showed that Tet2 −/− recipients developed a myeloid bias 4-6 months after BMT, whereas double-knockout recipients accumulated immature myeloid progenitors and developed dysmegakaryopoiesis ( Supplementary Fig. 2a ); around 10% of double-knockout recipients developed bone marrow failure ( Supplementary Fig. 2a ). Only doubleknockout recipients showed disrupted spleen features and infiltration of non-hematopoietic organs ( Supplementary Fig. 2b-d) .
The impact of dual gene loss was prominent in HSPCs. Before transplantation (1 month after poly(I:C) injection) and 4-6 months after transplantation, HSPCs were most abundant for the doubleknockout and Tet2 −/− genotypes ( Fig. 1h,i) . Strikingly, doubleknockout recipients showed a marked increase in the Lin − Sca1 + c-Kit + (LSK) stem/progenitor cell pool ( Fig. 1j,k) .
Interestingly, double-knockout recipients and some non-transplanted double-knockout mice developed lymphoid disease. Multiple B cell diseases occurred, including mature B cell (B220 + CD19 − ) salivary gland infiltration, mature B cell (largely B220 + ) lymphoma that was transplantable and caused acute lymphocytic leukemia (ALL) in recipients, and B cell (B220 + CD19 − ) ALL ( Supplementary  Fig. 3a-c) . T cell thymic lymphoma was observed in 50% of doubleknockout secondary recipients ( Supplementary Fig. 3d,e) . These data support a tumor-suppressor role for DNMT3A and TET2 in lymphoid lineages, similar to that observed in Tet2 −/− mice overexpressing the DNMT3A R882H allele 31 .
Overall, mice transplanted with double-knockout bone marrow display multiple hematological abnormalities, including CMML-like disease, bone marrow failure and lymphoid diseases, establishing a synergistic impact for combined Dnmt3a and Tet2 loss.
Lineage gene activation and HSC gene repression in double-knockout HSCs
To probe the mechanisms of synergy, we examined differences in gene expression among the four genotypes, focusing on HSCs (CD150 + CD48 − LKS) to explore early changes that led to a 'preleukemic' state. To maintain consistency with our previous Dnmt3a research 17 , we used HSCs from BMT recipient mice for all analysis. In comparison to wild-type HSCs, double-knockout cells shared many differentially expressed genes with Tet2 −/− cells, with additional alter-ations relative to HSCs with either single-knockout genotype ( Fig. 2a and Supplementary Table 1 ). Gene set enrichment analysis (GSEA) with lineage-specific 'fingerprint' gene sets 32 showed that genes specifically associated with HSCs and nucleated red blood cells (RBCs) had significantly altered expression ( Fig. 2b) . Although both Tet2 −/− and double-knockout HSCs downregulated HSC-specific genes (Fig. 2b) , the expression of HSC-associated transcription factors was similar to that in wild-type HSCs (Supplementary Fig. 4a-d) . Differences in gene expression could not be attributed to compensation from other DNA methylation regulators ( Supplementary Fig. 4e-g) . Double-knockout HSCs in comparison to Tet2 −/− HSCs showed further upregulation of RBC signature genes, which were conversely downregulated in Dnmt3a −/− HSCs. Double-knockout HSCs also upregulated a number of B cell signature genes ( Fig. 2b) .
Further examination showed upregulation of genes specific to other lineages in Tet2 −/− and double-knockout HSCs ( Fig. 2c and Supplementary Fig. 4j ). Strikingly, genes encoding regulators of RBC differentiation, Klf1 (EKLF) and the Epo receptor (Epor), were markedly upregulated in double-knockout HSCs (Fig. 2c) , with expression levels from highest to lowest across the genotypes following the order double knockout > Tet2 −/− > wild type > Dnmt3a −/− . This observation suggests that TET2 represses these genes in wild-type HSCs, supporting the GSEA analysis. Expression of master regulators of pan-lymphoid and B cell programs, Ikzf1 and Ebf1, respectively, followed a similar pattern, consistent with lymphoid disease development ( Fig. 2c and Supplementary Fig. 4h ). The pro-myeloid transcription factors Cebpa and Cebpe were upregulated in Tet2 −/− and double-knockout HSCs ( Fig. 2c and Supplementary Fig. 4i ), in alignment with their bias toward myeloid differentiation. These results indicate that Dnmt3a loss alone preserves the stem cell program but, in conjunction with Tet2 loss, leads to derepression of lineage-specific regulators, augmenting the progenitor-like features observed with Tet2 loss.
Expression of RBC-related KLF1 target genes is promoted in double-knockout HSCs
We further examined the cluster of genes downregulated in Dnmt3a −/− HSCs, upregulated in Tet2 −/− HSCs and further upregulated in double-knockout HSCs ( Fig. 2a , area between dashed lines). Gene ontology analysis focused on distinctions in gene expression between double-knockout and Tet2 −/− HSCs identified enrichment of hematopoiesis-and immune-response-related genes in doubleknockout HSCs (Fig. 2d) . In particular, genes controlled by KLF1 were enriched ( Fig. 2e,f) 33, 34 . Similarly, the target genes of other lineage-specific transcription factors such as CEBPα and EBF1 were also upregulated in double-knockout HSCs ( Supplementary  Fig. 4k,l) 35, 36 . These findings suggest that multiple lineage-specific and stem cell programs coexist in double-knockout HSCs, creating a self-renewal status, which seems to resemble the proposed 'seesaw' model in induced pluripotency 37 . Notably, upregulation of KLF1 and its downstream targets is also found in human patients with AML who harbor both DNMT3A and TET2 mutations but not in patients carrying DNMT3A mutations alone or in patients in whom neither gene is mutated ( Supplementary Fig. 5a,b) . Thus, Klf1 upregulation in double-knockout HSCs parallels that seen in human patients and could be a characteristic, if not a driving event, in leukemogenesis.
Klf1 and Epor erythroid genes influence double-knockout HSPC self-renewal
HSCs normally express differentiation-associated genes at a low level; such 'lineage priming' may accelerate differentiation 38 . The upregulation of RBC signature genes and other lineage-specific transcription 1 0 1 6 VOLUME 48 | NUMBER 9 | SEPTEMBER 2016 Nature GeNetics A r t i c l e s factors in double-knockout HSCs suggests that these cells may be more primed for differentiation than their wild-type counterparts. Paradoxically, double knockout results in deficiency of mature erythroid cells and marked anemia ( Fig. 1f,g) .
A similar scenario is observed in TCGA human patients with AML who have increased expression of KLF1 (group 2 in TCGA AML analysis) and are enriched in TET2 and DNMT3A co-mutations (4/6 DNMT3A-TET2 double-mutant patients fall into this cluster) 10 . Of the group 2 patients with increased KLF1 expression, a few had erythroleukemia (n = 2) and megakaryocytic leukemia (n = 1), but the majority belonged to another non-erythro/megakaryocytic leukemia subtype biased toward myeloid development with a clinical manifestation of anemia. Overall, data from TCGA and our study indicate that KLF1 upregulation does not promote erythroid differentiation in the context of simultaneous loss of TET2 and DNMT3A, instead possibly influencing self-renewal.
To test this hypothesis, we performed short hairpin RNA (shRNA)mediated knockdown of Klf1 or Epor in double-knockout HSPCs. Upon Klf1 or Epor knockdown, there was a reduction in colony-forming units (CFUs) from double-knockout HSPCs plated in semisolid medium (M3434 medium with erythropoietin (EPO), IL-3, IL-6 and stem cell factor (SCF)) ( Fig. 3a) . Epor knockdown resulted in a replating deficiency of double-knockout cells ( Fig. 3a) . Furthermore, Epor or Klf1 knockdown reduced expression of the self-renewal marker c-Kit on double-knockout HSPCs (Fig. 3b) , indicating that Epor and Klf1 might promote the self-renewal of double-knockout HSPCs in vitro. Knockdown of Klf1 or Epor with additional shR-NAs achieved similar effects (data not shown). These data suggest that pathways downstream of KLF1 and EPOR, such as JAK-STAT signaling, might contribute to the self-renewal of double-knockout HSCs. Indeed, decreases in total and phosphorylated levels 10 2 0 10 2 10 3 10 4 10 5 0 10 2 10 3 10 4 10 5 0 10 2 10 3 10 4 10 5 0 10 2 10 3 10 4 10 5 0 10 2 10 3 10 4 10 5 0 10 2 10 3 10 4 10 5 0 10 2 10 3 10 4 10 5 0 10 2 10 3 10 4 10 5 0 10 2 10 3 10 4 10 5 0 10 2 10 3 10 4 10 5 0 10 2 10 3 10 4 10 5 0 10 2 10 3 10 4 10 5 0 10 2 10 3 10 4 10 5 0 10 2 10 3 10 4 10 5 0 10 2 10 3 10 4 10 5 0 10 2 10 3 10 4 10 5 0 of JAK2, as well as decreased expression of BCL2L1 (BCL-XL), were observed upon Epor knockdown (Fig. 3c) . Treatment with the JAK2 inhibitor ruxolitinib or the BCL-XL-specific inhibitor WEHI-539 (ref. 39 ) also reduced the number of CFUs and the replating capacity of double-knockout HSPCs (Fig. 3d) .
Similar to the effect of Klf1 and Epor knockdown, treatment with ruxolitinib decreased the expression levels of c-Kit in replated doubleknockout cells (Fig. 3e) . Overall, these assays suggest that the RBC gene signature may contribute to abnormal self-renewal of doubleknockout HSCs rather than promoting RBC differentiation.
DNMT3A and TET2 maintain DNA methylation in HSCs
To investigate DNA methylation changes, we performed whole-genome bisulfite sequencing (WGBS) in HSCs (Supplementary Fig. 6a ).
Because of the complexity of comparing DNA methylation differences among wild-type, single-knockout and double-knockout cells, we identified changes in a two-step process. First, we defined all differ-entially methylated regions (DMRs) in each mutant in comparison to wild type ( Fig. 4a) . Then, we examined the methylation level of these DMRs in the other genotypes, identifying dynamic methylation alteration patterns (DMAPs). This strategy identified 22,075 DMRs, which were categorized into six major DMAPs ( Fig. 4b and Supplementary  Fig. 6b-d) . Dnmt3a loss was the major driver of alteration in DNA methylation, with the majority of hypomethylated Dnmt3a −/− DMRs also hypomethylated in double-knockout cells ( Fig. 4c,d) .
Tet2 −/− HSCs displayed the least DMRs ( Fig. 4c) .
By identifying DMAPs, we also discovered genotype-specific DMRs (for example, types I, II and VI in Fig. 4b ). In addition, some DMRs (type IV) gained methylation in Tet2 −/− cells and lost methylation in Dnmt3a −/− cells, with intermediate methylation levels in doubleknockout HSCs, consistent with counteractive TET2 and DNMT3A action at these loci. Some of these DMRs correspond to the edges of large and small unmethylated regions (canyons and UMRs, respectively) ( Supplementary Fig. 6e,f) , supporting our hypothesis that A r t i c l e s DNMT3A and TET2 can oppose each other at DNA methylation canyons 40 . Across most DMRs, methylation changes were primarily enriched at the edges of UMRs, except for the Tet2 −/− -specific class (type VI) in which hypermethylation occurred exclusively in the center of the DMR, indicating that TET2 normally maintains low levels of methylation in these regions ( Supplementary Fig. 6e,g) .
We were particularly interested in synergistic (type III) DMRs, in which methylation levels decreased in Dnmt3a −/− cells from levels in wild-type cells and then further dropped in double-knockout HSCs (average 26-55% decrease) ( Fig. 4b and Supplementary Fig. 6b ).
This behavior suggests that TET2 contributes to maintenance of the methylation signal; this is likely through hydroxymethylation, but bisulfite treatment cannot distinguish between 5mC and 5hmC. When both proteins were absent, 5mC as well as 5hmC was completely depleted from these DMRs, resulting in starkly absent methylation in double-knockout HSCs at these loci.
Enhancer regions are increasingly recognized as epigenetically dynamic and influenced by DNMT and TET proteins 41, 42 . Enhancer methylation across hematopoietic lineages 43 was not strongly altered. However, of the DMRs that overlapped enhancers, most were hypomethylated in Dnmt3a −/− and double-knockout HSCs (Supplementary Fig. 7a-c) . Interestingly, long-term HSC (LT-HSC) and short-term HSC (ST-HSC) enhancers had low methylation levels in HSCs, whereas B cell-and RBC-specific enhancer sites became hypomethylated in both Dnmt3a −/− and double-knockout HSCs (Fig. 4e) . This observation suggests that loss of DNMT3A function 'primes' HSCs to differentiate into these lineages by depleting methylation at specific lineage-relevant enhancers. Changes in enhancer methylation correlated poorly with gene expression, possibly owing to imprecision in linking enhancers with specific transcription units 43 . 
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A r t i c l e s
Synergistic loss of 5mC and 5hmC in double-knockout HSCs
To determine how loss of DNMT3A and TET2 affected hydroxymethylation, we mapped 5hmC using the cytosine-5-methylenesulfonate immunoprecipitation (CMS-IP) method 44, 45 . DNMT3A and TET2 both contributed to 5hmC maintenance, with TET2 loss resulting in the greatest redistribution of 5hmC ( Fig. 5a) .
We also identified genotype-specific 5hmC patterns by applying the strategy described above to find differentially hydroxymethylated regions (DhMRs) and then classifying them into dynamic hydroxymethylation alteration patterns (DhMAPs). This strategy identified five DhMAP clusters (Fig. 5b) . Despite global loss of 5hmC in Tet2 −/− and double-knockout HSCs (clusters 4 and 5), some loci showed increased 5hmC specifically in Tet2 −/− and double-knockout HSCs (clusters 1 and 2). Increased 5hmC may be due to ectopic TET1 or TET3 action in the absence of TET2 (Fig. 5b) . These results show that TET2 loss not only reduces global 5hmC but also leads to 5hmC redistribution. Finally, we found that both DNMT3A and TET2 contribute to global maintenance of 5hmC. Hydroxymethylation decreased in Dnmt3a −/− and Tet2 −/− HSCs (Fig. 5c,d) , with the lowest 5hmC signal in double-knockout HSCs, as expected because oxidation to 5hmC requires the presence of 5mC.
We next investigated whether patterns of dynamic methylation (DMAPs) and hydroxymethylation (DhMAPs) were correlated across the genome. We examined 5hmC enrichment in the six major DMAPs, finding that type III (synergistic) DMRs were more enriched for 5hmC than other DMRs (Fig. 5e,f) . This indicates that, in the absence of DNMT3A, TET2-mediated hydroxymethylation of persisting 5mC sites accounts for the apparent maintenance of methylation at type III DMRs. In other words, the methylation signal remaining at these DMRs seems to actually be 5hmC, which is read as a methylation mark after bisulfite treatment. The 5hmC at these DMRs was absent in Tet2 −/− HSCs, and neither 5mC nor 5hmC was present at these regions in double-knockout HSCs (Fig. 5g,h) .
Because 5hmC can be a step in DNA demethylation, we investigated how 5hmC and 5mC alterations correlated by examining the overlap between DMRs and DhMRs. We found that DMRs and DhMRs significantly overlapped (Fig. 6a) . We then examined the trends in overlap and exclusion of DMR and DhMR groups (Fig. 6b) . As expected, type III DMRs tended to overlap with cluster 3 DhMRs, in comparison with random overlap between DMRs from all DMAPs and DhMRs from all clusters (Fig. 6b) , confirming that synergistic DMRs are sites of DNMT3A and TET2 competition. Additionally, type V DMRs and cluster 4 DhMRs were observed together at canyon edges ( Fig. 6b and Supplementary Fig. 8a) . Finally, genes associated with type III DMRs and cluster 3 DhMRs overlapped with statistical significance (Supplementary Fig. 8b) . Together, these data show that DMAPs and DhMAPs are correlated in the epigenome and support the notion of competition (at type V DMRs and cluster 4 DhMRs at canyon edges) and cooperation (at type III DMRs and cluster 3 DhMRs) of DNMT3A and TET2 in modifying the epigenome.
5hmC-linked HSC gene activation and lineage transcription factor repression
With the global 5hmC and 5mC dynamics across all four genotypes, we have shown that various interactions between DNMT3A and TET2 activity occur in different regions. We next asked whether 5hmC and 5mC could globally affect gene expression. By assigning genes expressed in HSCs of one genotype into quantiles by their expression levels, we found that 5mC distribution correlated only poorly with gene expression (Fig. 6c) , whereas 5hmC displayed a 'bimodal' pattern in which highly expressed genes (with greater than median FPKM values) showed enriched 5hmC distribution in promoter and gene body regions whereas genes in the lower quartiles showed 5hmC enrichment at their transcription start sites (TSSs) (Fig. 6d) . Our analysis is consistent with previous studies and indicates that the genic distribution of 5hmC is more associated with gene expression than that of 5mC.
We next focused on 5hmC distribution in genes whose expression changed the most in mutant HSCs. Consistent with previous reports 7,46-49 , 5hmC signal was associated with both repression and activation of gene expression (Figs. 6e-h and 7a, and Supplementary  Fig. 8c) . At HSC fingerprint genes 32 that were downregulated in double-knockout HSCs (Figs. 2b and 6e) , 5hmC levels were decreased in the gene body and promoter regions (Fig. 6f) . These observations support a gene-activating role for 5hmC on genes highly expressed in HSCs. A specific example is the Mpl locus, encoding the thrombopoietin receptor critical to HSCs, where loss of 1 0 2 0 VOLUME 48 | NUMBER 9 | SEPTEMBER 2016 Nature GeNetics A r t i c l e s 5hmC in the promoter and gene body correlated with decreased gene expression in double-knockout cells (Fig. 7a) .
In contrast, at the TSSs of RBC-associated genes that were upregulated in doubleknockout HSCs (Figs. 2b and 6g) , 5hmC was depleted in double-knockout cells (Fig. 6h) . Notably, RBC gene expression was generally inversely proportional to 5hmC content in the TSS region: higher 5hmC signal correlated with lower relative gene expression (in comparison to wild-type cells), and vice versa (Fig. 6f,h) . The loss of TSS 5hmC in conjunction with marked gene upregulation in double-knockout HSCs strongly suggests that 5hmC has a repressive role to constrain RBC gene expression in HSCs. This is consistent with a previous study that showed that genes in the bottom 20% of all expressed transcripts were highly enriched for 5hmC signal in their TSS regions 46, 48 . Together, these data support the view that 5hmC in the TSS region maintains gene expression at a low, 'poised' level.
In addition to 5hmC repressing RBC genes, 5hmC in the TSS region of the myeloid transcription factor Cebpe was associated with gene repression (Supplementary Figs. 4e and 8d) . Except for the RBC and HSC fingerprint gene sets (Supplementary Fig. 8b) , there was not a significant correlation of gene expression with 5hmC distribution in specific genomic regions (Supplementary Fig. 9a,b) . Together, these data indicate distinct functions for gene body versus promoter 5hmC.
DNMT3A and TET2 competitively repress Klf1 in HSCs
We then examined genes in cluster 3 for alterations in expression, identifying Klf1, as well as the master lymphoid regulator Ikzf1, as members that exhibited both synergistic loss of methylation in double-knockout HSCs and increased 5hmC in Dnmt3a −/− HSCs. Both of these genes were upregulated in double-knockout HSCs ( Fig. 7b  and Supplementary Fig. 9c ). Klf1 is in the RBC gene group that gains 5hmC in Dnmt3a −/− cells and loses 5hmC in the TSS region when TET2 is lost. Klf1 also harbors a type III (synergistic) DMR in its upstream promoter region (Fig. 7b) , which exhibited high 5hmC signal in Dnmt3a −/− HSCs (Fig. 7b) . Consistent with the low expression of Klf1 in wild-type and Dnmt3a −/− HSCs, the type III DMR in the Klf1 promoter region also exhibited trimethylation of histone H3 at lysine 27 (H3K27me3) in Dnmt3a −/− HSCs, which was absent in Tet2 −/− and double-knockout HSCs (Fig. 7b) . Thus, combining Klf1 and target gene expression, we conclude that DNA methylation and elevated 5hmC levels in the TSS region of Klf1 are both associated with repression of Klf1 expression in HSCs. Conversely, loss of 5hmC in Tet2 −/− and double-knockout HSCs is associated with increased Klf1 gene expression.
The promoter region of Ikzf1 undergoes similar changes, resembling Klf1 in 5mC-5hmC dynamics (Supplementary Fig. 9c) , in contrast to the Mpl locus in which decreased gene body 5hmC signal was associated with lower gene expression in the absence of TET2 (Fig. 7a) . On the basis of our analysis, we propose that DNA methylation at regulatory regions of lineage-specific transcription factors npg decreases in Dnmt3a −/− HSCs, but TET2 represses the expression of these transcription factors by maintaining 5hmC marks in the TSS region. The loss of both TET2 and DNMT3A is required for full activation of Klf1 and Ikzf1. Therefore, we conclude that, in HSCs, both TET2 and DNMT3A repress differentiation-associated transcription factors by hydroxymethylation and methylation activity in regulatory regions (Fig. 7c) .
DISCUSSION
DNMT3A and TET2 modify cytosine at CpG dinucleotides, with DNMT3A adding a methyl group whereas TET2 oxidizes it to 5hmC. Classical epistasis theory predicts that combining null mutations in DNMT3A and TET2 should result in a double mutant that resembles either single mutant. However, we show that double-null mice display a distinct phenotype and accelerated disease progression. Our data, together with the fact that DNMT3A and TET2 mutations co-occur in T cell lymphoma and AML in humans, suggest an unconventional interplay between DNMT3A and TET2.
Here we substantiate these complex interactions, as DNA methylation and hydroxymethylation profiles indicate that these proteins have both independent and interdependent roles ( Figs. 4 and 5) . With regard to demethylation instigated by TET2, its deficiency would be redundant with loss of DNMT3A if the critical 5mC that TET2 acts upon is generated by DNMT3A. Indeed, enhancers display dominant hypomethylation in Dnmt3a −/− HSCs, which is maintained in doubleknockout HSCs, particularly at HSC-associated enhancers; this is consistent with the participation of DNMT3A in repression of the stem cell program 17, 50 .
We also observe contribution of TET2 to HSC maintenance: the gene bodies of highly expressed HSC-specific genes are laden 1 0 2 2 VOLUME 48 | NUMBER 9 | SEPTEMBER 2016 Nature GeNetics A r t i c l e s with 5hmC, and loss of Tet2 correlates with diminished expression of these genes. This finding supports previously reported observations in embryonic stem cells and erythropoiesis of 5hmC as a stable epigenetic mark 7, 26, [47] [48] [49] 51 .
Notably, as compound knockout mice (Dnmt3a-Dnmt3b, Tet1-Tet2, and Tet2-Tet3 double knockouts) of DNA methylation regulators have been developed, the layered regulatory nature of DNA (hydroxy)methylation has been suggested 17, 50, 52, 53 . The loss of one regulator results in a redistribution of other regulators and DNA modifications, contributing to the mutant phenotypes, as shown here.
Finally, we observe that TET2 is associated with repression of lineage differentiation genes, particularly in relation to 5hmC at the TSS. With loss of Tet2, accentuated in the double knockout, RBC-and myeloid-associated transcription factors are upregulated. This observation is consistent with studies using embryonic stem cells where a repressive role for 5hmC has been suggested 7, 46, 48 . Furthermore, Tet1-null mice develop a lymphoid gene signature associated with bivalent marks 54 and 5hmC derivatives can inhibit transcription elongation 55 , linking TET proteins to poised gene repression.
Overall, we find that TET-mediated hydroxymethylation seems to contribute to both differentiation and self-renewal through gene activation and repression. DNMT3A may also contribute to both activities by repressing HSC genes and generating 5mC for TET action. Dnmt3a loss exacerbates the expression changes in cells with loss of Tet2, indicating that both factors contribute to repression. Indeed, TET2 represses some lineage-specific factors as effectively as DNMT3A, which could explain the dramatic upregulation of Klf1 in double-knockout cells. Such parallel and sometimes redundant roles likely lead to the synergistic development of malignancies with TET2 and DNMT3A co-mutation in mouse and human.
Thus, we propose a dual-function model for 5hmC in HSCs (Fig. 7c) . Hydroxymethylation, added by TET2 in the gene body and some promoter regions, maintains HSC gene expression ( Fig. 7c) . Concomitantly, 5mC (generated by DNMT3A) and 5hmC (generated by TET2 oxidation of 5mC) both maintain the repression or 'primed' state of lineage-specific transcription factors. When both types of marks are lost and these genes are derepressed, their upregulation promotes abnormal self-renewal and primes HSCs for transformation (Fig. 7c) .
The increase in KLF1-regulated gene expression in both mice and humans is striking. Priming of lineage-specific genes is thought to enhance differentiation upon stress 38, 56, 57 . Paradoxically, erythroid differentiation is abrogated in the double knockout, suggesting instead self-renewal, potentially contributing to leukemogenesis. Lymphoid master transcription factors are similarly upregulated. A recent study on induced pluripotency demonstrated that the combination of ectodermal and mesendodermal inducer genes can substitute for Oct4 and Sox2 in the reprograming process 37 , suggesting that the concurrent expression of normally opposing transcription factors can drive an undifferentiated state. Our observations provide a similar example, in which dysregulated lineage programs in HSCs contribute to disease development. Targeting these pathways may provide therapeutic avenues for patients with malignancies who carry both DNMT3A and TET2 mutations.
URLs. Browser tracks for the data presented here can be accessed at http://dldcc-web.brc.bcm.edu/lilab/jianzhos/Tet2_3aDKO_Project/ Tet2_3aDKO_hub.txt. The Cancer Genome Atlas (TCGA) Data Portal, https://tcga-data.nci.nih.gov/tcga/; R language, http://www. r-project.org/.
METHODS
Methods and any associated references are available in the online version of the paper.
Accession codes. The RNA-seq, DNA methylation, histone ChIPseq and CMS-IP data have been deposited in the Gene Expression Omnibus (GEO) under accession GSE72148.
Cytosine-5-methylenesulfonate immunoprecipitation. Genomic DNA was isolated using the Qiagen DNeasy Blood and Tissue kit. Purified genomic DNA was sonicated into ~300-bp fragments using Covaris focused ultrasonicators. Sheared DNA was ligated with methylated adaptors using the Illumina TruSeq DNA library preparation kit followed by sodium bisulfite treatment (Life Technologies, Methylcode Bisulfite Conversion Kit) to convert 5hmC to CMS. CMS fragments were enriched using antibody to CMS that binds to protein A/G Dynabeads. Enriched fragments were cleaned up using the phenol/ chloroform/isoamyl alcohol method and then amplified using KAPA HiFi Uracil+ polymerase (Kapa Biosystems) with 12 PCR cycles. Amplified libraries were sequenced using the Illumina HiSeq 2500 platform. The paired-end 100-bp 5hmc CMS reads for the four genotypes (wild-type, Dnmt3a −/− , Tet2 −/− and double-knockout HSCs) were aligned to the mouse reference genome (mm9) using the BSMAP alignment algorithm 64 with at most four mismatches as described previously 40 . For each sample, the sum read number was normalized to 30 million. To compare 5hmc CMS distribution among the four genotypes, quantile normalization for the 5hmc CMS density of each was performed using the Wiq function. The 5hmc densities of DMRs and flanking regions (2 kb) were computed using the Profile function in DANPOS 2.2.0 (ref. 65 ). The paired identification of DhMRs was performed using the Dregion function of DANPOS 2.2.0 in comparison of the wild-type and three knockout genotypes (Dnmt3a −/− , Tet2 −/− and double knockout) of HSCs with an FDR cutoff of 1 × 10 −5 . The three sets of DhMRs were merged into reference DhMRs. Reference DhMRs more than 200 bp in length were retained. The average CMS signals of reference DhMRs were computed using BEDtools 63 . The method of k-means clustering was used to classify the clusters of DhMRs among the four genotypes with the optimal number of clusters estimated by R package fpc. Five clusters of DhMRs were identified from 40,969 DhMRs that showed different 5hmc enrichment among the four genotypes ( Supplementary Table 3 ).
Functional enrichment analysis.
For RNA-seq functional enrichment analysis, the GSEA pre-rank test was used to test the enrichment of the LOLLIPOP lineage-specific gene set for differentially expressed genes in mutant HSCs versus wild-type HSCs (double knockout versus wild type) 32, 66 . DAVID v6.7 was also used to perform functional enrichment analysis for differentially expressed genes (double knockout versus Tet2 −/− ) for target pathway analysis. For DMR functional enrichment analysis, we used DAVID v6.7 to perform functional enrichment analysis for differentially expressed genes (double knockout versus Tet2 −/− ) and the gene set of different DMR types 67 .
Significant P values were adjusted by the Bonferroni method and visualized by MEV. DMR-associated genes were extracted if the DMRs were located within 2 kb of the genes.
